Osivax Receives $19.5M BARDA Award to Advance Next-Generation Influenza Vaccine for Pandemic and Seasonal Preparedness Funding to accelerate development of Osivax’ broad-spectrum influenza A vaccine candidate, OVX836 Lyon, France and Liège, Belgium – August 26, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced it has …
Archives de l’étiquette : OVX836
Osivax Publishes Phase 2a Results Supporting Co-Administration of OVX836 with Seasonal Flu Vaccine in Vaccines Journal
Osivax Publishes Phase 2a Results Supporting Co-Administration of OVX836 with Seasonal Flu Vaccine in Vaccines Journal Co-administration of OVX836 with seasonal inactivated influenza vaccine (Fluarix® Tetra) was well-tolerated and demonstrated a favorable safety profile Robust complementary immune responses were induced, with no major interference observed Lyon, France – July 10, 2025 – Osivax, a biopharmaceutical company …
Osivax Announces Last Patient Last Visit in Phase 2a Trial Evaluating a Booster Dose of Broad-Spectrum Influenza Vaccine OVX836
Osivax Announces Last Patient Last Visit in Phase 2a Trial Evaluating a Booster Dose of Broad-Spectrum Influenza Vaccine OVX836 Final results expected in H2 2025 Lyon, France – June 5, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that all participants have completed their final visit …
I4ID 2024
Lyon, France – PosterSéverine Valsesia, Immuno R&D engineer, to present a poster entitled “A mix of OVX836, a NP-based influenza vaccine candidate, with a commercial seasonal vaccine is immunogenic and synergistically protective in mice”. François Fasquelle, Clinical Immunology Project Manager, to present a poster entitled “OVX836, a NP-based broad-spectrum influenza vaccine candidate, is safe, immunogenic …
World Vaccines Congress Europe 2024
Barcelona, Spain – Oral PresentationNicola Groth, Chief Medical Officer, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical Update of OVX836, a Novel Broad-Spectrum Type A Influenza Vaccine Candidate”.
Influenza Vaccines for the World 2024
Siena, Italy – Oral PresentationNicola Groth, Chief Medical Officer of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical development update on OVX836, a T-cell based broad-spectrum influenza vaccine”.
World Congress Vaccine Washington 2024
Washington, DC – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical development update on OVX836, a T-cell based broad-spectrum influenza vaccine”.
Osivax Announces Vaccination of Last Patient in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs
Osivax Announces Vaccination of Last Patient in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs 478 participants were enrolled across Australia Full immunogenicity and safety results expected in the second half of 2024 Lyon, France – March 26, 2024 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that …
Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836
Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836 Grant to support preclinical evaluation of OVX836 in providing protection against pandemic influenza strains OVX836 has already been evaluated in several Phase 2 clinical trials against seasonal influenza with initial signals of broad-spectrum protection Lyon, France – December 5, 2023 …
Osivax Announces Publication in The Lancet Infectious Diseases of Phase 2a Data for Broad-Spectrum Influenza Vaccine Candidate, OVX836
Osivax Announces Publication in The Lancet Infectious Diseases of Phase 2a Data for Broad-Spectrum Influenza Vaccine Candidate, OVX836 OVX836 demonstrated positive safety and immunogenicity data across three dose levels A notable signal of protection of 84% was observed against symptomatic influenza infection Lyon, France – July 28, 2023 – Osivax, a a biopharmaceutical company developing vaccines to provide …